Research in the Seyfried lab is focused on the integration of proteomics, systems biology, and molecular biology to tackle fundamental questions related to the pathogenesis of Alzheimer’s Disease (AD) and other neurodegenerative disorders. In particular, we utilize high resolution liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to identify and quantify proteins and post-translational modifications (PTMs). Combining tools in both molecular and cellular biology, we also explore the relationship between the function of these proteins and their PTMs in the development of these devastating diseases.
Our funded projects are currently focused on the development of mass spectrometry-based techniques for:
(2) Identification and quantification of protein post-translational modifications including ubiquitination, phosphorylation, methylation
(3) Proteomic biomarker discovery in cerebrospinal fluid (CSF), plasma and platelets in Alzheimer’s Disease and other related neurodegenerative diseases
(4) Proteogenomic applications to identify rare coding changes at the peptide level in AD candidate risk genes
September 2018, Promotion: Dr. Nick Seyfried promoted to Associate Professor. Congratulations, Nick!
June 2018, New Publication: Dr. Srikant Rangaraju's paper titled, Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer's disease-related proteins, is published in Molecular Neurodegeneration. Jun 28;13(1):34.
May 2018, Thesis Defense: BCDB graduate student Isaac
May 2018, paper accepted: Isaac’s paper titled “RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease” was recently accepted for publication by the Journal of Biological Chemistry.
March 2018, paper accepted: